David L. Paterson

951 total papers · 99.3k total citations
582 papers, 61.2k citations indexed

About

David L. Paterson is a scholar working on Molecular Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, David L. Paterson has authored 582 papers receiving a total of 61.2k indexed citations (citations by other indexed papers that have themselves been cited), including 283 papers in Molecular Medicine, 224 papers in Epidemiology and 172 papers in Infectious Diseases. Recurrent topics in David L. Paterson's work include Antibiotic Resistance in Bacteria (283 papers), Antibiotics Pharmacokinetics and Efficacy (149 papers) and Antibiotic Use and Resistance (116 papers). David L. Paterson is often cited by papers focused on Antibiotic Resistance in Bacteria (283 papers), Antibiotics Pharmacokinetics and Efficacy (149 papers) and Antibiotic Use and Resistance (116 papers). David L. Paterson collaborates with scholars based in Australia, United States and United Kingdom. David L. Paterson's co-authors include Robert A. Bonomo, Anton Y. Peleg, Harald Seifert, Louis B. Rice, Nina Singh, Gunnar Kahlmeter, Christian G. Giske, Yehuda Carmeli, John Stelling and Anna-Pelagia Magiorakos and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David L. Paterson

564 papers receiving 59.4k citations

Hit Papers

Multidrug-resistant, exte... 2000 2026 2008 2017 2011 2000 2008 2005 2006 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
    2011 10.0k citations Anna-Pelagia Magiorakos, Arjun Srinivasan et al. Clinical Microbiology and Infection profile →
  2. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
    2000 2.7k citations David L. Paterson, Susan Swindells et al. profile →
  3. Acinetobacter baumannii : Emergence of a Successful Pathogen
    2008 2.6k citations Anton Y. Peleg, Harald Seifert et al. Clinical Microbiology Reviews profile →
  4. Extended-Spectrum β-Lactamases: a Clinical Update
    2005 2.6k citations David L. Paterson, Robert A. Bonomo Clinical Microbiology Reviews profile →
  5. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
    2006 2.5k citations John E. McGowan, David L. Paterson et al. Clinical Infectious Diseases profile →
  6. Antimicrobial Resistance in ESKAPE Pathogens
    2020 1.4k citations David M. P. De Oliveira, Brian M. Forde et al. Clinical Microbiology Reviews profile →
  7. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
    2006 1.1k citations Jian Li, Roger L. Nation et al. The Lancet Infectious Diseases profile →
  8. Resistance in Gram-Negative Bacteria: Enterobacteriaceae
    2006 697 citations David L. Paterson The American Journal of Medicine profile →
  9. Predictors of Mortality in Staphylococcus aureus Bacteremia
    2012 685 citations S. J. van Hal, Slade O. Jensen et al. Clinical Microbiology Reviews profile →
  10. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain
    2010 579 citations Benjamin A. Rogers, Hanna E. Sidjabat et al. Journal of Antimicrobial Chemotherapy profile →
  11. Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
    2011 567 citations Samira M. Garonzik, Jian Li et al. Antimicrobial Agents and Chemotherapy profile →
  12. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
    2020 531 citations Matteo Bassetti, Roger Echols et al. The Lancet Infectious Diseases profile →
  13. Distribution ofLegionellaSpecies and Serogroups Isolated by Culture in Patients with Sporadic Community‐Acquired Legionellosis: An International Collaborative Survey
    2002 518 citations Victor L. Yu, Joseph F. Plouffe et al. The Journal of Infectious Diseases profile →
  14. A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use
    2005 506 citations Carlene A. Muto, Marian Pokrywka et al. Infection Control and Hospital Epidemiology profile →
  15. Peritoneal Dialysis-Related Infections Recommendations: 2005 Update
    2005 506 citations David L. Paterson et al. profile →
  16. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
    2017 476 citations David van Duin, Sandra S. Richter et al. Clinical Infectious Diseases profile →
  17. Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter
    2012 471 citations S. J. van Hal, David L. Paterson et al. Antimicrobial Agents and Chemotherapy profile →
  18. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
    2012 437 citations Zubair Qureshi, David L. Paterson et al. Antimicrobial Agents and Chemotherapy profile →
  19. Global dissemination of a multidrug resistant Escherichia coli clone
    2014 421 citations Nicola K. Petty, Nouri L. Ben Zakour et al. Proceedings of the National Academy of Sciences profile →
  20. Multidrug-Resistant Bacteria in the Community
    2016 417 citations David van Duin, David L. Paterson Infectious Disease Clinics of North America profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David L. Paterson 30.9k 19.1k 15.1k 13.2k 11.2k 582 61.2k
Ronald N. Jones 22.5k 0.7× 20.7k 1.1× 25.5k 1.7× 16.0k 1.2× 5.4k 0.5× 1.3k 56.8k
Robert A. Bonomo 30.3k 1.0× 9.2k 0.5× 5.3k 0.3× 11.7k 0.9× 9.8k 0.9× 722 39.5k
Yehuda Carmeli 19.9k 0.6× 8.7k 0.5× 8.3k 0.5× 5.8k 0.4× 6.6k 0.6× 331 34.0k
Patrice Nordmann 52.9k 1.7× 8.7k 0.5× 5.3k 0.4× 12.8k 1.0× 25.1k 2.2× 712 59.7k
David M. Livermore 23.7k 0.8× 6.5k 0.3× 4.3k 0.3× 8.7k 0.7× 8.3k 0.7× 405 31.8k
Laurent Poirel 44.2k 1.4× 6.9k 0.4× 3.9k 0.3× 10.4k 0.8× 20.9k 1.9× 522 48.6k
Rafael Cantón 15.6k 0.5× 8.4k 0.4× 7.0k 0.5× 4.6k 0.3× 6.6k 0.6× 759 30.2k
Fred C. Tenover 10.9k 0.4× 9.0k 0.5× 20.9k 1.4× 3.9k 0.3× 4.8k 0.4× 345 39.3k
Louis B. Rice 13.2k 0.4× 6.1k 0.3× 7.9k 0.5× 4.3k 0.3× 3.8k 0.3× 176 27.1k
Fernando Baquero 12.5k 0.4× 5.6k 0.3× 5.9k 0.4× 3.6k 0.3× 4.4k 0.4× 493 29.3k

Countries citing papers authored by David L. Paterson

Since Specialization
Citations

This map shows the geographic impact of David L. Paterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Paterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Paterson more than expected).

Fields of papers citing papers by David L. Paterson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Paterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Paterson. The network helps show where David L. Paterson may publish in the future.

Co-authorship network of co-authors of David L. Paterson

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Paterson. A scholar is included among the top collaborators of David L. Paterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Paterson. David L. Paterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George A. Bray Breakdown of academic impact, for papers by Stephen B. Kritchevsky Breakdown of academic impact, for papers by Deborah S. Hasin Breakdown of academic impact, for papers by Hertzel C. Gerstein Breakdown of academic impact, for papers by Roald Hoffmann Breakdown of academic impact, for papers by Nancy Eisenberg Breakdown of academic impact, for papers by A. Jamil Tajik Breakdown of academic impact, for papers by Roger Atkinson
Rankless by CCL
2026